ArticleJournal of the Endocrine Society2026
Excess mortality in radiotherapy-treated pituitary adenoma patients: 50-year follow-up.
Article in Journal of the Endocrine Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: We report the long-term survival and the causes of excess mortality in a cohort of pituitary adenoma (PA) patients treated with radiotherapy, with or without prior surgery at up to 50 years of follow-up. Objective: To evaluate long-term survival and causes of excess mortality in patients with PAs treated with radiotherapy, with or without prior surgery, and to examine the relationship between treatment factors, particularly radiotherapy dose and mortality outcomes over extended follow-up. Methods: 426 patients treated with radiotherapy at the Royal Marsden Hospital during 1962 and 1994 with or without prior surgery were followed up via the NHS Central Register to identify deaths and emigrations. Standardized mortality ratios (SMRs) and absolute excess risks (AERs) were calculated by comparing observed deaths with expected rates based on national age, sex, year, and period-specific mortality rates for England and Wales. Results: 260 deaths were recorded compared to 144 expected (SMR 1.8; AER 140.7). The main contributors to excess mortality were cerebrovascular disease (SMR 4.9; AER 61.4), endocrine/metabolic disease (SMR 5.6), and mental and behavioral disorders (SMR 5.0). Both all-cause and cerebrovascular-specific mortality were associated with increasing radiotherapy dose and with the use of surgery. Conclusion: Patients with PAs treated with surgery and radiotherapy have an increased mortality compared to the general population, with the principal contributor cerebrovascular accident mortality. The observed dose-response suggests a potential relationship between radiotherapy and vascular morbidity. The findings highlight the need for long-term surveillance and proactive management of vascular risk factors and in patients requiring radiotherapy and avoiding excessive radiotherapy doses. Whether modern high-precision fractionated radiotherapy techniques reduce the risk of cerebrovascular morbidity and mortality requires long-term studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.